FIELD: medicine.
SUBSTANCE: invention can be used for the investigation of TRAIL-mediated apoptosis mechanisms, and as a therapeutic agent for treating DR5-dependent tumours. The mutations Y189N/R191K/Q193R/H264R/I266L/D267Q/D269H or Y189N/R191K7 Q193R/H264R/I266L/D269H are introduced in human TRAIL found in plasmid DNA pET32a that is followed with the transformation of Escherichia coli BL21 (DE3) strain of the produced recombinant plasmid DNA, expression and recovery of target protein.
EFFECT: invention allows producing recombinant mutant human TRAIL with high antineoplastic activity.
3 dwg, 3 tbl, 5 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD OF PRODUCING HUMAN RECOMBINANT ANTI-TUMOUR PROTEIN DR5-B | 2018 |
|
RU2687435C1 |
| METHOD OF SUPPRESSING GROWTH OF TUMOURS WITH GENETICALLY MODIFIED VERSION OF TRAIL CYTOKINE | 2019 |
|
RU2727059C1 |
| PROTEIN CONSTRUCT BASED ON A RECEPTOR-SPECIFIC MUTANT VARIANT OF THE ANTITUMOR CYTOKINE TRAIL AS A HYBRID PROTEIN WITH A PEPTIDE SPECIFIC FOR INTEGRIN ΑVΒ3 FOR THE TREATMENT OF SOLID TUMORS | 2022 |
|
RU2802488C1 |
| METHOD FOR TUMOUR CELL DEATH INDUCTION | 2015 |
|
RU2620165C2 |
| APOPTOTIC Apo2L/TRAIL SENSITIVITY BY TESTING GalNac-T14 EXPRESSION IN CELLS/TISSUES | 2006 |
|
RU2416097C2 |
| MULTIFUNCTIONAL HYBRID RECOMBINANT PROTEIN MEDICINAL PRODUCTS FOR THE TREATMENT OF TUMOR DISEASES | 2022 |
|
RU2801367C1 |
| ANALYSES AND METHODS OF BIOMARKER APPLICATION | 2006 |
|
RU2409817C2 |
| COMBINATION OF ANTIBODY HAVING SELECTIVITY IN RELATES TO APOPTOSIS INDUCING LIGAND RECEPTOR ASSOCIATED WITH TUMOR NECROSIS FACTOR AND OTHER THERAPEUTIC AGENTS | 2002 |
|
RU2313368C2 |
| ANALYSES AND METHODS USING BIOMARKERS | 2005 |
|
RU2410438C2 |
| ANTIBODY SELECTIVE TO APOPTOSIS INDUCING LIGAND RECEPTOR ASSOCIATED WITH TUMOR NECROSIS FACTOR, AND USES THEREOF | 2001 |
|
RU2298013C2 |
